Pravachol
(pravastatin sodium)PreclinicalSmall molecule
Pravachol is one of 46 small molecule programs targeting Myelodysplastic Syndromes. It is currently in Preclinical.
1
Indications
16
Total Trials
0
Active Trials
45
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
51 competitors in Myelodysplastic Syndromes
#DrugCompanyPhaseTrials
1Dacogen
Sun Pharmaceutical Industries, Inc.Approved
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Cytosar
TevaApproved
Idamycin
PfizerApproved
Reblozyl
Bristol-Myers SquibbPhase 3
Evrenzo
AstellasPhase 3
Xospata
AstellasPhase 3
Rytelo
GGeron Corporation
Approved
Venclexta
AbbViePhase 2
Fludara
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fasting Conditions3 trials
Acute Myeloid Leukemia2 trials
Statin2 trials
Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fed Conditions
Completed·—·Phase 1·NCT01146093·24 enrolled
7 more indications
Small Cell Lung Cancer1 trial
Drug1 trial
The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00017758·56 enrolled
Myelodysplastic Syndromes1 trial
Effectiveness1 trial
Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00006412·630 enrolled
Interaction1 trial
Regulatory
FDA Approval Timeline[4]
Oct 31, 1991
PRAVACHOL
NDA NDA019898
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for pravastatin sodium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details